Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis

Schlesinger et al., Diabetologia, doi:10.1007/s00125-023-05928-1

Schlesinger et al., Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic.., Diabetologia, doi:10.1007/s00125-023-05928-1

May 2023 Source PDF

Twitter
Facebook

All Studies Meta

Systematic review and meta analysis showing significantly lower COVID-19 mortality and severity with metformin use. Authors analyze 169 studies of diabetes patients, with 23 reporting mortality results and 34 reporting severity results for metformin.

Currently there are 65 metformin studies and meta analysis shows:

Outcome	Improvement
Mortality	32% lower [27‑37%]
Ventilation	30% lower [11‑44%]
ICU admission	17% lower [5‑28%]
Hospitalization	18% lower [10‑24%]
Cases	4% fewer [-6‑13%]

Important missing comments or errors? Let us know.

risk of death, 31.0% lower, RR 0.69, p < 0.001.

risk of severe case, 22.0% lower, RR 0.78, p < 0.001.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Schlesinger et al., 19 May 2023, peer-reviewed, 10 authors.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Metformin All

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit